Skip to main content

Table 3 Duration of ventilation, intensive care unit stay, and hospital stay (safety population)

From: A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Duration (days)a IC43 100 μg with adj
(N = 104)
IC43 100 μg w/o adj
(N = 98)
IC43 200 μg with adj
(N = 101)
Placebo
(N = 98)
Total
(N = 401)
Ventilation 18.5 (13.4) 18.7 (18.6) 18.5 (17.2) 17.9 (14.8) 18.4 (16.0)
ICU stay 26.6 (17.7) 24.3 (17.8) 24.0 (16.9) 23.5 (16.0) 24.6 (17.1)
Hospital stayb 15.2 (20.3) 13.9 (14.6) 14.4 (20.9) 12.4 (17.6) 14.0 (18.5)
  1. aData are presented as mean (standard deviation); includes non-censored data only. Data were either censored or missing for 14 patients (ventilation), 11 patients (ICU stay) and 32 patients (hospital stay). bNot including ICU stay. ICU intensive care unit, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide adjuvant